merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
![Merus logo](https://files.capedge.com/F-1/0001193125-18-359219/g569434g02u78.jpg)
Company profile
Ticker
MRUS
Exchange
Website
CEO
Sven Lundberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merus B.V.
SEC CIK
MRUS stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Jul 24
8-K
Entry into a Material Definitive Agreement
30 May 24
424B5
Prospectus supplement for primary offering
30 May 24
424B5
Prospectus supplement for primary offering
28 May 24
8-K
Other Events
28 May 24
8-K/A
Submission of Matters to a Vote of Security Holders
10 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Departure of Directors or Certain Officers
8 May 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
Latest ownership filings
SC 13G/A
INCYTE CORP
24 Jul 24
4
Fabian Zohren
3 Jul 24
3
Fabian Zohren
3 Jul 24
4
Peter B. Silverman
28 Jun 24
144
Notice of proposed sale of securities
27 Jun 24
5
Harry Shuman
26 Jun 24
4
Peter B. Silverman
20 Jun 24
144
Notice of proposed sale of securities
17 Jun 24
4
Harry Shuman
12 Jun 24
4
Harry Shuman
6 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 178.93 mm | 178.93 mm | 178.93 mm | 178.93 mm | 178.93 mm | 178.93 mm |
Cash burn (monthly) | 8.70 mm | (no burn) | 15.60 mm | 14.85 mm | 14.80 mm | 12.49 mm |
Cash used (since last report) | 33.62 mm | n/a | 60.32 mm | 57.40 mm | 57.20 mm | 48.28 mm |
Cash remaining | 145.31 mm | n/a | 118.61 mm | 121.52 mm | 121.73 mm | 130.65 mm |
Runway (months of cash) | 16.7 | n/a | 7.6 | 8.2 | 8.2 | 10.5 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 156 |
Opened positions | 70 |
Closed positions | 6 |
Increased positions | 32 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 2.17 tn |
Total shares | 63.83 mm |
Total puts | 292.80 k |
Total calls | 123.30 k |
Total put/call ratio | 2.4 |
Largest owners | Shares | Value |
---|---|---|
Commodore Capital | 4.36 mm | $196.33 bn |
RTW Investments | 4.11 mm | $185.05 bn |
INCY Incyte | 4.00 mm | $0.00 |
Flynn James E | 3.02 mm | $0.00 |
Biotechnology Value Fund L P | 2.75 mm | $0.00 |
Deerfield Management | 2.65 mm | $119.30 bn |
FHI Federated Hermes Inc - Ordinary Shares | 2.25 mm | $101.26 bn |
Bay City Capital | 2.11 mm | $50.26 mm |
Samlyn Capital | 2.08 mm | $93.51 bn |
Boxer Capital | 1.90 mm | $85.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Fabian Zohren | Share Options Ordinary Shares | Grant | Acquire A | No | No | 54.45 | 183,943 | 10.02 mm | 183,943 |
27 Jun 24 | Silverman Peter B. | Common Shares | Sell | Dispose S | No | Yes | 60 | 10,000 | 600.00 k | 0 |
27 Jun 24 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | Yes | 17.94 | 7,453 | 133.71 k | 10,000 |
27 Jun 24 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | Yes | 17.94 | 2,547 | 45.69 k | 2,547 |
27 Jun 24 | Silverman Peter B. | Share Option Common Shares | Option exercise | Dispose M | No | Yes | 17.94 | 7,453 | 133.71 k | 0 |
27 Jun 24 | Silverman Peter B. | Share Option Common Shares | Option exercise | Dispose M | No | Yes | 17.94 | 2,547 | 45.69 k | 0 |
17 Jun 24 | Silverman Peter B. | Common Shares | Sell | Dispose S | No | Yes | 56.519 | 62,000 | 3.50 mm | 0 |
17 Jun 24 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | Yes | 17.94 | 9,253 | 166.00 k | 62,000 |
17 Jun 24 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | Yes | 17.94 | 2,747 | 49.28 k | 52,747 |
17 Jun 24 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | Yes | 25.9 | 41,577 | 1.08 mm | 50,000 |
News
Canaccord Genuity Maintains Buy on Merus, Maintains $67 Price Target
25 Jul 24
Stifel Maintains Buy on Merus, Raises Price Target to $99
17 Jun 24
B of A Securities Maintains Buy on Merus, Lowers Price Target to $76
5 Jun 24
BMO Capital Maintains Outperform on Merus, Raises Price Target to $91
4 Jun 24
Truist Securities Maintains Buy on Merus, Raises Price Target to $88
4 Jun 24
Press releases
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
24 Jul 24
Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
3 Jun 24
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
2 Jun 24
Merus Announces Pricing of Upsized Public Offering of Common Shares
29 May 24
Merus N.V. Announces Proposed Public Offering of Common Shares
28 May 24